Clinical trial
Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs…
NCT00498108 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00498108 |
|---|---|
| Title | Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects |
| Official title | An Open-label Extension Trial to Investigate the Safety and Tolerability of Long-term Treatment With Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Idiopathic Restless Legs Syndrome |
| Intervention type | Drug |
| Interventions | Rotigotine |
| Enrollment | 341 |
| Start date | Jan 1, 2006 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Jul 9, 2007 |
| Last update posted | Sep 25, 2014 |
| Countries | Germany |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: